NFE2L2 and acute kidney injury: Here, we show that this applies to cisplatin AKI and further demonstrates that inhibition of intracellular ROS by JP4-039 without engaging the Nrf2 antioxidant pathway is sufficient to block AKI pathophysiology and tubular injury.